Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Chronic Myeloid Leukemia Excellence Forum

Chronic Myeloid Leukemia
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

David Andorsky, MD
Conference Coverage
01/10/2024
At the 65th ASH Annual Meeting, David Andorsky, MD, discussed an interim analysis of the AIM4CML trial, which indicated that asciminib treatment continued to demonstrate efficacy and tolerability among patients with CML chronic phase.
At the 65th ASH Annual Meeting, David Andorsky, MD, discussed an interim analysis of the AIM4CML trial, which indicated that asciminib treatment continued to demonstrate efficacy and tolerability among patients with CML chronic phase.
At the 65th ASH Annual Meeting,...
01/10/2024
Oncology
Ehab Atallah, MD
Videos
10/19/2022
Ehab Atallah, MD, provides an update on the management of patients with CML, highlighting new available agents and the role of monitoring for MRD.
Ehab Atallah, MD, provides an update on the management of patients with CML, highlighting new available agents and the role of monitoring for MRD.
Ehab Atallah, MD, provides an...
10/19/2022
Oncology
Podcasts
06/04/2021
Jorge Cortes, MD, shares findings from the OPTIC trial on a dosing regimen of ponatinib for patients with CP-CML. These data are being presented at the 2021 ASCO Annual Meeting.
Jorge Cortes, MD, shares findings from the OPTIC trial on a dosing regimen of ponatinib for patients with CP-CML. These data are being presented at the 2021 ASCO Annual Meeting.
Jorge Cortes, MD, shares...
06/04/2021
Oncology
Dr Atallah Assesses Outcomes Following the Discontinuation of TKIs in CML
Interview
02/16/2021
Ehab L. Atallah, MD, discusses the findings of a study which looked at outcomes after TKI cessation in patients with CML.
Ehab L. Atallah, MD, discusses the findings of a study which looked at outcomes after TKI cessation in patients with CML.
Ehab L. Atallah, MD, discusses...
02/16/2021
Oncology
Andreas Hochhaus, MD, Talks About the ASCEMBL Trial, Eliminating LSCs in CML
Podcasts
12/11/2020
In this podcast, Dr Hochhaus discusses the significance of the ASCEMBL trial, and proposes the question of how to eliminate persisting leukemic stem cells (LSCs) in CML.
In this podcast, Dr Hochhaus discusses the significance of the ASCEMBL trial, and proposes the question of how to eliminate persisting leukemic stem cells (LSCs) in CML.
In this podcast, Dr Hochhaus...
12/11/2020
Oncology
Andreas Hochhaus, MD, on Asciminib vs Bosutinib for Pretreated CML-CP
Podcasts
11/30/2020
Dr Hochhaus discusses the use of asciminib versus bosutinib for the treatment of patients with CML-CP previously given ≥2 TKIs.
Dr Hochhaus discusses the use of asciminib versus bosutinib for the treatment of patients with CML-CP previously given ≥2 TKIs.
Dr Hochhaus discusses the use of...
11/30/2020
Oncology
Study Findings Support Use of FISH to Identify Chromosomal Abnormalities in CML
Interview
10/16/2020
Zhenya Tang, MD, PhD, discusses the findings and clinical significance of a study he led on the use of FISH to identify chromosomal abnormalities in patients with CML.
Zhenya Tang, MD, PhD, discusses the findings and clinical significance of a study he led on the use of FISH to identify chromosomal abnormalities in patients with CML.
Zhenya Tang, MD, PhD, discusses...
10/16/2020
Oncology
Impact of Care Cost on TKI Adherence in Patients With CML
Commentary
10/09/2020
Gary Lyman, MD, comments on the clinical significance and findings of a study he co-conducted on the link between generic imatinib availability and trends in TKI use among patients with CML.
Gary Lyman, MD, comments on the clinical significance and findings of a study he co-conducted on the link between generic imatinib availability and trends in TKI use among patients with CML.
Gary Lyman, MD, comments on the...
10/09/2020
Oncology
The Evolving Treatment Landscape for CML
Podcasts
09/26/2020
Matt Kalaycio, MD, discusses how treatment for CML has evolved in the past 2 decades, and touches on the IRIS trial, which greatly impacted the treatment landscape for this disease.
Matt Kalaycio, MD, discusses how treatment for CML has evolved in the past 2 decades, and touches on the IRIS trial, which greatly impacted the treatment landscape for this disease.
Matt Kalaycio, MD, discusses how...
09/26/2020
Oncology
TKI Therapy Interruption Recommended for Pregnant Patients With CML
Interview
09/20/2020
Elisabetta Abruzzese, MD, PhD, discusses the history of research pertaining to patients with CML who are pregnant or planning to start a family.
Elisabetta Abruzzese, MD, PhD, discusses the history of research pertaining to patients with CML who are pregnant or planning to start a family.
Elisabetta Abruzzese, MD, PhD,...
09/20/2020
Oncology

Advertisement

Advertisement

Advertisement

Advertisement